AIM ImmunoTech floats Ampligen alongside Revolution's daraxonrasib, with no trial yet

AIM ImmunoTech has set out a strategy of using its experimental immune-stimulating drug Ampligen (rintatolimod) alongside daraxonrasib, the RAS inhibitor from Revolution Medicines, in pancreatic cancer. The idea appeared in company materials for investors dated 5 November 2026.

The proposal is a company hypothesis. No clinical trial of the pairing has been set up, and nothing available on file reports efficacy or safety data for it. Nor is there any sign of an agreement with Revolution Medicines. For now, the idea shows how AIM wants to place Ampligen in a field where targeted RAS-directed drugs are a focus of development. It does not change the company's commercial footing.

AIM also restated earlier observations from a named-patient programme in the Netherlands, which gives access to the drug outside a formal trial. The details of those observations are not given in the material reviewed. Ampligen is not approved by the US Food and Drug Administration for pancreatic cancer, so any use remains investigational or via named-patient access.

The nearer-term test is DURIPANC, a Phase 2 study of Ampligen with AstraZeneca's PD-L1 antibody durvalumab. AIM expects topline results in the first quarter of 2027, with further analyses planned for the third quarter of 2027. Those readouts, not the daraxonrasib concept, are the dated milestones the company has put forward.